Osteoporosis management in post-menopausal women

Minerva Ginecologica

Volumn 64, Issue 3, 2012, Pages 181-194

  Christenson, E S ^a   Jiang, X ^a   Kagan, R ^c,d   Schnatz, P F ^a,b,e,f  

^a READING HOSPITAL AND MEDICAL CENTER   (United States)

^b Department of Internal Medicine ^*  (United States)

^c East Bay Physicians Medical Group   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f Internal Medicine   (United States)

Author keywords

Menopause; Osteoporosis; Osteoporosis, post menopausal

Indexed keywords

ALPHA TOCOPHEROL; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; ESTROGEN; PARATHYROID HORMONE[1-34]; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ARTICLE; BREAST CANCER; CELLULITIS; CONSTIPATION; DERMATITIS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ECZEMA; ESOPHAGUS DISEASE; FEMUR SUBTROCHANTERIC FRACTURE; FLU LIKE SYNDROME; FLUSHING; FRACTURE; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY DISEASE; LEG CRAMP; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; MEDLINE; MUSCLE CRAMP; NAUSEA; NEPHROLITHIASIS; NOSE IRRITATION; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; QUALITY OF LIFE; SEIZURE; SIDE EFFECT; STROKE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

CALCIUM; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC;

EID: 84864384238     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement Online. [cited 2012 April 17]. Available at: http://consensus.nih.gov/2000/ 2000Osteoporosis111html.htm
2. Fraser L-A, Vogt KN, Adachi JD, Thabane L. Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Ther Clin Risk Manag 2011;7:157-66.
3. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-75.
4. ACOG Committee Opinion No. 407: low bone mass (osteopenia) and fracture risk. Obstet Gynecol 2008;111:1259-61.
5. Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 2010;17:25-54.
6. Osteoporosis - PubMed Health. [Accessed 2012 March 7; cited 2012 April 17]. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001400/
7. Schnatz PF, Marakovits KA, Dubois M, O'Sullivan DM. Osteoporosis screening and treatment guidelines: are they being followed? Menopause 2011;18:1072-8.
8. FRAX® WHO fracture risk assessment tool. [Accessed 2012 March 7; cited 2012 April 17]. Available at: http://www.shef.ac.uk/FRAX/
9. Tang BMP, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370:657-66.
10. Reid IR, Bolland MJ, Grey A. Effect of calcium supplementation on hip fractures. Osteoporos Int 2008;19:1119-23.
11. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2007;92:1415-23.
12. Seeman E. Evidence that calcium supplements reduce fracture risk is lacking. Clin J Am Soc Nephrol 2010;5(Suppl 1):S3-11.
13. Meier C, Kränzlin ME. Calcium supplementation, osteoporosis and cardiovascular disease. Swiss Med Wkly 2011;141:w13260.
14. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040.
15. Dietary Reference Intakes for Calcium and Vitamin D. [Accessed 2012 March 7; cited 2012 April 17]. Available at: http://www.iom.edu/Reports/2010/Dietary- Reference-Intakes-for-Calcium-and-Vitamin-D/DRI-Values.aspx
16. Vitamin D and Bone Health. [Accessed 2012 March 7; cited 2012 April 17]. Available at: http://www.nof.org/aboutosteoporosis/prevention/vitamind
17. Singhellakis PN, Malandrinou FC, Psarrou CJ, Danelli AM, Tsalavoutas SD, Constandellou ES. Vitamin D deficiency in white, apparently healthy, free-living adults in a temperate region. Hormones (Athens) 2011;10:131-43.
18. Garriguet D. Bone health: osteoporosis, calcium and vitamin D. Health Rep 2011;22:7-14.
19. Schnatz PF, Nudy M, O'Sullivan DM, Ethun K, Appt SE, Clarkson TB. Identification of a mechanism for increased cardiovascular risk among individuals with low vitamin D concentrations. Menopause 2011;18:994-1000.
20. Bordelon P, Ghetu MV, Langan RC. Recognition and management of vitamin D deficiency. Am Fam Physician 2009;80:841-6.
21. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. J Clin Endocrinol Metab 2011;96:53-8.
22. Nazrun AS, Norazlina M, Norliza M, Nirwana SI. The anti-inflammatory role of vitamin e in prevention of osteoporosis. Adv Pharmacol Sci 2012;142702;7.
23. Jimi E, Nakamura I, Ikebe T, Akiyama S, Takahashi N, Suda T. Activation of NF-κB IS Involved in the Survival of Osteoclasts Promoted by Interleukin-1. Journal of Biological Chemistry 1998;273:8799-805.
24. Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A 1991;88:5134-8.
25. Sato F, Ouchi Y, Masuyama A, Nakamura T, Hosoi T, Okamoto Y et al. Effects of estrogen replacement on insulin-like growth factor I concentrations in serum and bone tissue and on interleukin 1 secretion from spleen macrophages in oophorectomized rats. Calcif. Tissue Int 1993;53:111-6.
26. Ahmad NS, Khalid BAK, Luke DA, Ima Nirwana S. Tocotrienol offers better protection than tocopherol from free radical-induced damage of rat bone. Clin Exp Pharmacol Physiol 2005;32:761-70.
27. Hermizi H, Faizah O, Ima-Nirwana S, Ahmad Nazrun S, Norazlina M. Beneficial effects of tocotrienol and tocopherol on bone histomorphometric parameters in sprague-dawley male rats after nicotine cessation. Calcif Tissue Int 2009;84:65-74.
28. Hapidin H, Othman F, Soelaiman I-N, Shuid AN, Luke DA, Mohamed N. Negative effects of nicotine on bone-resorbing cytokines and bone histomorphometric parameters in male rats. J Bone Miner Metab 2007;25:93-8.
29. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010. [Accessed 2012 March 7; cited 2012 April 17]. Available at: http://www.nof.org/sites/default/files/pdfs/NOF-ClinicianGuide2009-v7.pdf
30. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64.
31. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:404-15.
32. American College of Obstetricians and Gynecologists Women's Health Care Physicians. Osteoporosis. Obstet Gynecol 2004;104(Suppl):66S-76S.
33. Frediani B, Cavalieri L, Cremonesi G. Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Clin Drug Investig 2009;29:359-79.
34. Muratore M, Quarta E, Grimaldi A, Calcagnile F, Quarta L. Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates. Drug Des Devel Ther 2011;5:445-54.
35. Solomon CG. Bisphosphonates and osteoporosis. N Engl J Med 2002;346:642.
36. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001;28:465-73.
37. Eekman DA, Bultink IEM, Heijboer AC, Dijkmans BAC, Lems WF. Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskelet Disord 2011;12:167.
38. Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture. Ther Clin Risk Manag 2011;7:257-64.
39. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.
40. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
41. Frediani B. Effects of two administration schemes of intramuscular clodronic acid on bone mineral density: a randomized, open-label, parallel-group study. Clin Drug Investig 2011;31:43-50.
42. Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8.
43. McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 2004;19:728-36.
44. Kim SY, Kim MJ, Cadarette SM, Solomon DH. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res Ther 2010;12:R30.
45. Bhuriya R, Singh M, Molnar J, Arora R, Khosla S. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2010;142:213-7.
46. Adler RA, Gill RS. Clinical utility of denosumab for treaunent of bone loss in men and women. Clin Interv Aging 2011;6:119-24.
47. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94.
48. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006;137:429-38.
49. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al. Bisphophonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-89.
50. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. Position paper on bisphophonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12.
51. Lewiecki EM, Bilezikian JP, Jankowski LG, McCloskey EV, Miller PD, Morgan SL et al. Proceedings of the 2011 Santa Fe Bone Symposium. Journal of Clinical Densitometry: Assessment of Skeletal Health 2012;15:1e20.
52. Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporosis Int 2011;22:373-90.
53. Ghinoi V, Brandi ML. Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders. Expert Opin Pharmacother 2002;3:1643-56.
54. Black DM, Reid IR, Boonen S, Bucci-Rechrweg C, Cauley JA, Cosman F et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27:243-54.
55. Update of Safety Review Follow-up to the October 1, 2007 Early Communication about the Ongoing Safety Review of Bisphosphonates. [Accessed 2012 March 7; cited 2012 April 17]. Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformation-forPatientsandProviders/ DrugSafetyInformationfor-HeathcareProfessionals/ucm136201.htm
56. Watts NB, Diab DL. Long term use of bisphosphonates in osteoporosis. JCEM 2010;95:1555.
57. Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000;109:267-76.
58. Rizzoli R, Kraenzlin M, Krieg MA, Mellinghoff HU, Lamy O, Lippuner K. Indications to teriparatide treatment in patients with osteoporosis. Swiss Med Wkly 2011;141:w13297.
59. Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006;7:113-21.
60. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
61. Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with post-menopausal osteoporosis. J Clin Endocrinol Metab 2010;95:1838-45.
62. Cosman F, Eriksen EF, Recknor C, Miller PD, Guanabens N, Kasperk C et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011;26:503-11.
63. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-65.
64. Cauley JA, Robbin J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density - The Women's Health Initiative Randomized Trial. JAMA 2003;290:1729-38.
65. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.
66. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L et al. Health outcomes after stopping conjugated equine estrogens among post-menopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14.
67. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2012;19:257-71.
68. Kawate H, Takayanagi R. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clin Interv Aging 2011;6:151-60.
69. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-24.
70. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34.
71. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-52.
72. Franek E. Denosumab - a new option in the treatment of osteoporosis. Endokrynol Pol 2011;62:79-83.
73. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
74. McClung MR, Lewiecki M, Bolognese MA, Peacock M, Weinstein RL, Ding B et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.. [Accessed 2012 March 7; cited 2012 April 17]. Available at: http://www.asbmr.org/itinerary/ presentationdetail.aspx?id=96cfd7dc-4143-4150-8e9b-49d44817c916
75. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial. [Accessed 2012 March 7; cited 2012 April 17]. Available at: http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol- newsArticle&id=1626692
76. Przedlacki J. Strontium ranelate in post-menopausal osteoporosis. Endokrynol Pol 2011;62:65-72.